Evidence map›Paper›PMID 38539439›Full record

ReviewCancers2024

A-Z of Epigenetic Readers: Targeting Alternative Splicing and Histone Modification Variants in Cancer.

Nivedhitha Mohan, Roderick H Dashwood, Praveen Rajendran

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nivedhitha MohanCenter for Epigenetics & Disease Prevention, Texas A&M Health, Houston, TX 77030, USA.
Roderick H DashwoodCenter for Epigenetics & Disease Prevention, Texas A&M Health, Houston, TX 77030, USA.ORCID 0000-0003-0351-4034
Praveen RajendranCenter for Epigenetics & Disease Prevention, Texas A&M Health, Houston, TX 77030, USA.ORCID 0000-0002-6221-7366

Funding

Dietary HDAC Inhibitors in Colon Cancer PreventionR01CA122959 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DASHWOOD, RODERICK H · 2008 to 2023
$4.3M
Immunoepigenetic targeting of MHC regulators in FAPR01CA257559 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Roderick H Dashwood, Eduardo Vilar Sanchez · 2023 to 2026
$2.3M
NCI NIH HHS CA122959NCI NIH HHS CA257559NCI NIH HHS R01 CA122959NCI NIH HHS R01 CA257559
6 · The paper itself

Abstract

Epigenetic 'reader' proteins, which have evolved to interact with specific chromatin modifications, play pivotal roles in gene regulation. There is growing interest in the alternative splicing mechanisms that affect the functionality of such epigenetic readers in cancer etiology. The current review considers how deregulation of epigenetic processes and alternative splicing events contribute to pathophysiology. An A-Z guide of epigenetic readers is provided, delineating the antagonistic 'yin-yang' roles of full-length versus spliced isoforms, where this is known from the literature. The examples discussed underscore the key contributions of epigenetic readers in transcriptional regulation, early development, and cancer. Clinical implications are considered, offering insights into precision oncology and targeted therapies focused on epigenetic readers that have undergone alternative splicing events during disease pathogenesis. This review underscores the fundamental importance of alternative splicing events in the context of epigenetic readers while emphasizing the critical need for improved understanding of functional diversity, regulatory mechanisms, and future therapeutic potential.

Indexed as

alternative splicingepigenetic readerisoformprecision oncology

Identifiers

PMID38539439
PMCPMC10968829
OpenAlexW4392649071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.